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Abstract – Toxoplasma gondii causes one of the most common protozoal diseases of humans and animals world-
wide. With the aim of designing an effective vaccine against T. gondii infection, we examined the immunogenicity
of a DNA vaccine expressing heat shock protein 40 (HSP40) against challenge with T. gondii (type I RH and type
II Pru) strains in Kunming mice. The plasmid pVAX1-HSP40 was constructed and used to immunize mice by intra-
muscular injection for three sequential immunizations with two-week intervals. This immunization regimen signifi-
cantly reduced parasite cyst burden in pVAX1-HSP40-immunized mice (1871.9 ± 142.3) compared with control
mouse groups immunized with pVAX1 (3479.2 ± 204.4), phosphate buffered saline (3024.4 ± 212.8), or left
untreated (3275.0 ± 179.8) as healthy controls (p < 0.01). However, immunization failed to protect mice against chal-
lenge with the virulent RH strain. There was a significant increase in T lymphocyte subclasses (CD3e+CD4+ T and
CD3e+CD8a+ T lymphocytes) in splenic tissues in immunized mice compared with controls (p < 0.05). However,
the level of antibodies, lymphocyte proliferation and concentration of cytokines (IFN-c, IL-2, IL-4, IL-10 and
IL-12p70) were not significantly different between immunized and control mouse groups (p < 0.05). These data indi-
cate that pVAX1-HSP40 induced specific immune responses and achieved a significant reduction in the number of
brain cysts in Pru-infected mice, and thus can be tested in future immunization studies along with plasmids containing
other immunogenic proteins as a cocktail vaccine to fully abolish chronic toxoplasmosis.
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Résumé – L’immunisation avec de l’ADN plasmidique exprimant la protéine de choc thermique HSP40 con-
fère une protection prophylactique contre une infection chronique à Toxoplasma gondii chez des souris Kun-
ming. Toxoplasma gondii provoque l’une des maladies à protozoaires les plus courantes chez les humains et les
animaux dans le monde entier. Dans le but de concevoir un vaccin efficace contre l’infection à T. gondii, nous
avons examiné l’immunogénicité d’un vaccin ADN exprimant la protéine de choc thermique HSP40 contre des
souches de T. gondii (type I RH et type II Pru) chez des souris Kunming. Le plasmide pVAX1-HSP40 a été
construit et utilisé pour immuniser des souris par injection intramusculaire pour trois immunisations séquentielles
avec des intervalles de deux semaines. Ce schéma d’immunisation a réduit significativement la charge de kyste
parasitaire chez les souris immunisées par pVAX1-HSP40 (1871.9 ± 142.3) par rapport aux groupes de souris
témoins immunisés avec pVAX1 (3479.2 ± 204.4), traités par solution saline tamponnée au phosphate
(3024.4 ± 212.8) ou non traités (3275.0 ± 179.8) comme témoins sains (p < 0.01). Cependant, l’immunisation n’a
pas réussi à protéger les souris contre la souche virulente RH. Il y avait une augmentation significative des sous-
classes de lymphocytes T (lymphocytes T CD3e+ CD4+ T et CD3e+CD8a+) dans les tissus spléniques chez les
souris immunisées par rapport aux témoins (p < 0.05). Cependant, le taux d’anticorps, la prolifération
lymphocytaire et la concentration de cytokines (IFN-c, IL-2, IL-4, IL-10 et IL-12p70) n’étaient pas
significativement différents entre les groupes de souris immunisés et témoins (p < 0.05). Ces données indiquent que
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pVAX1-HSP40 induit des réponses immunitaires spécifiques et réduit significativement le nombre de kystes cérébraux
chez les souris infectées par Pru, et peut donc être testé dans des études de vaccination futures avec des plasmides
contenant d’autres protéines immunogènes dans un cocktail de vaccins, pour abolir la toxoplasmose chronique.
Introduction
The Apicomplexan protozoan Toxoplasma gondii is the
agent of a major zoonotic disease, toxoplasmosis, affecting
mainly immunocompromized individuals and naïve pregnant
women [3, 5, 8, 29]. Current therapeutic medicines are not
highly effective or cause adverse effects [1, 36]. Currently,
there are no approved human vaccines against toxoplasmosis
disease, and efforts are ongoing to identify protective antigens
and the best strategies for vaccine development [17, 35, 39].
Effective therapeutic interventions are thus desirable and will
be facilitated by a better understanding of the extent of the
efficacy achieved by vaccination using key proteins to prevent
T. gondii infection.
Heat shock proteins (HSPs) are ubiquitous constitutively or
inducibly expressed proteins that act as molecular chaperones
assisting in the assembly, folding, stabilization, and transloca-
tion of other cellular proteins. They are generally upregulated
in response to various stress conditions [33], and bind unfolded,
misfolded, or denatured proteins to prevent unwanted aggrega-
tion [32]. HSPs play roles in cell cycle progression, and tran-
scriptional and posttranslational processes, such as protein
folding, stability, transportation, and degradation, and they also
play roles in the pathogenesis of inflammation and cancer
[20, 27, 37]. HSPs are highly effective and versatile molecules
in promoting immune responses against tumors and infections
[7]. They can also mediate antigen presentation and activation
of immune cells, such as lymphocytes, macrophages and
dendritic cells [6]. They are presumed to have immunogenic
properties due to their ability to bind, stabilize, and protect
the antigen from degradation [34].
HSP40 plays a regulatory role in DNA duplication, protein
modification, degradation and translocation across the mem-
brane, endocytosis, and cell-signal transduction [15, 24]. It is
involved in the pathogenicity of viruses such as Simian virus
40 [21] and protozoa such as Plasmodium falciparum [30].
HSP40 plays an essential role in the mechanisms of T. gondii
bradyzoite development [9], and the nucleotide sequences of
HSP40 genes are highly conserved among T. gondii genotypes,
indicating that HSP40 might be a good vaccine candidate to
counter the development and dissemination of T. gondii [23].
In this study, we tested the hypothesis that a DNAvaccine could
provide a safe and reliable strategy against acute and chronic
infection with T. gondii, and that HSP40 is a target of protective
immune responses. Our results indicate that HSP40-based DNA
vaccine effectively inhibited parasite cyst burden and induced
antigen-specific adaptive cellular immune response.
Materials and methods
Ethics statement
All animal experiments were performed strictly in accor-
dance with the guidelines of the Animal Ethics Procedures
of the People’s Republic of China. Ethical approval to conduct
the procedures that involved mouse immunization and parasite
challenge was obtained from the Animal Ethics and Adminis-
tration Committee of Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences (Approval No.
LVRIAEC2012-011).
Animals and parasites
Female, 6–8-week old specific pathogen-free (SPF) grade,
Kunming mice were purchased from the Laboratory Animal
Center of Lanzhou Biological Product Institute (Lanzhou,
China). Mice were housed in a High-density Touch Screen
Mouse IVC System (FENGSHI, Qingdao, China), and their
food and bedding materials were provided by Beijing Keao
corporation (http://u6452366.b2bname.com/). Tachyzoites of
T. gondii RH strain (Genotype I) maintained in vitro in African
green monkey kidney cells and cysts of T. gondii Pru strain
(Genotype II) separated from brain tissues of orally Pru-infected
Kunming mice were used in the parasite challenge experiments
to test the efficacy of the immunization. T. gondii lysate antigen
(TLA) was prepared as described previously [22].
Constructions of recombinant pET30a-HSP40
and pVAX1-HSP40 plasmids
Total RNA was extracted from T. gondii RH tachyzoites
using the E.Z.N.A. Total RNA Kit I (Omega, Norcross,
Georgia, USA). Based on the reference sequence of the ME49
strain (ToxoDB: TGME49_265310), a pair of specific
primers (forward primer: 50-GGGGTACCATGGGGAAGGAC-
TACTACAGAA-30; reverse primer: 50-CGCGGATCCCTA-
CACGTTCGGAAGCAGTT-30) was designed and used to
amplify the coding sequence of the T. gondii HSP40 gene.
The KpnI and BamHI restriction sites are underlined in the pri-
mers. RT-PCR was carried out following the instructions of the
PrimeScript One Step RT-PCR Kit (TaKaRa, Dalian, China).
The amplification reaction was performed in the thermocycler
with the following program: a reverse transcription reaction at
50 C for 0.5 h; then denaturation at 94 C for 2 min; followed
by 35 cycles of denaturation at 94 C for 1 min, annealing at
56.6 C for 30 s, extension at 72 C for 1.5 min, and was ended
with a final extension at 72.0 C for 10 min. The PCR products
were purified using the E.Z.N.A. Gel Extraction Kit (Omega)
and were inserted into the pMD18-T linear vector (TaKaRa),
generating plasmid pMD-HSP40. The pMD-HSP40 plasmids
were digested using the restriction enzymes KpnI/BamHI in
order to obtain the HSP40 fragment. Then, the pET30a(+) or
pVAX1 plasmids were digested using the same restriction
enzymes, and the HSP40 fragment was ligated to them using
T4 DNA ligase (TaKaRa), constructing the recombinant
pET30a-HSP40 or pVAX1-HSP40 plasmids, respectively. The
sequences of the inserts were confirmed by sequencing. The
pET30a-HSP40 plasmid was used to prepare recombinant
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HSP40 protein (rHSP40). The concentration of pVAX1-
HSP40 was measured at 260 nm and 280 nm using a BioMate
3S spectrophotometer (Thermo, Waltham, Massachusetts,
USA). The plasmid was adjusted to a final concentration of
1 lg/lL.
Preparation of rHSP40 protein
The pET30a-HSP40 plasmid was constructed using the
same method and primers used to construct the pVAX1-
HSP40 plasmid above. This pET30a-HSP40 plasmid was
transfected into Escherichia coli BL21 competent cells by heat
shock at 42 C for 1.5 min, and was induced to express the
rHSP40 protein in vitro using isopropyl-b-D-thiogalactoside
(IPTG, Promega, Fitchburg, Wisconsin, USA). The products
with 6-His tag were purified by Ni-NTA His Bind Resin
(Novagen, Madison, Wisconsin, USA). The purified rHSP40
protein was used to coat the wells of the 96-well plates in
the enzyme-linked immunosorbent assay (ELISA) to measure
the concentrations of specific anti-rHSP40 antibodies.
Transfection and expression of pVAX1-HSP40
in vitro
To confirm whether the HSP40 protein can be expressed
in eukaryotic cells, we used human embryonic kidney cells
293 (HEK293), indirect immunofluorescence and Western
blotting analyses, as described previously [13]. HEK293 cells
were seeded at a concentration of 2.5 · 105 cells/well into a
six-well tissue culture plate until the cells reached 70%
confluence. Transfection with pVAX1-HSP40 or empty
pVAX1 (vector control) was performed with LipofectAMINE
2000 reagent (Invitrogen, Carlsbad, California, USA), as
instructed by the manufacturer. Approximately 72 h post-
transfection, the cells were fixed with 4% paraformaldehyde
(PFA) for 30 min, permeabilized with 0.1% Triton X-100 for
30 min, and incubated with goat anti-T. gondii serum (1:50
in PBS) and the Alexa Fluor 488-AffiniPure donkey anti-
goat IgG (H + L) diluted 1:1000 in PBS (Jackson Immuno
Research Inc., West Grove, Pennsylvania, USA) was added
and the samples were kept at ambient temperature in the dark
for 60 min. The fluorescent images were obtained using a
Zeiss Axioplan 2 fluorescence microscope (Carl Zeiss,
Oberkochen, Germany).
Next, ~107 cells (transfected with either pVAX1-HSP40 or
pVAX1) were collected at 72 h post transfection, suspended
into 200 lL of SDS-PAGE loading buffer (Sangon, Shanghai,
China) and incubated at 100 C for 10 min. The products were
separated using 5%–12% gradient bis-tris gels (Sangon) and
transferred to the nitrocellulose membrane (PALL, Port Wash-
ington, New York, USA) using a TRANS-BLOT SD CELL
(Bio-Rad, Hercules, California, USA). The membrane was
blocked with 5% non-fat milk in PBS and incubated with goat
anti-T. gondii serum (1:50 in PBS), and subsequently with
HRP-conjugated rabbit anti-goat IgG (H + L) (Agrisera,
Vännäs, Sweden) (1:5000 in PBS). A DAB-HRP Color Devel-
opment Kit was used, following the manufacturer’s instructions
(CWBIO, Beijing, China).
Immunization protocol
Kunming mice were randomly allocated into four groups
(42 mice per group) and intramuscularly (i.m.) immunized
three times at a two-week interval. The experimental mouse
groups included: Group I injected with 100 lL of sterile
phosphate-buffered saline (PBS; pH 7.4) containing 100 lg
pVAX1-HSP40; Group II injected with 100 lL of PBS con-
taining 100 lg of the empty pVAX1 (vector control); Group
III injected with 100 lL of sterile PBS alone; and Group IV
received no treatment and served as a healthy control. Spleen
tissues collected aseptically from immunized and control mice
(n = 3 mice per group) prior to the challenge were chopped
with scissors into small pieces, and the splenic tissue fragments
were pressed gently through a fine nylon mesh in order to
prepare single cell suspensions.
Efficacy of immunization against acute
and chronic toxoplasmosis
The aim of these experiments was to test the efficacy of
immunization with pVAX1-HSP40 against acute and chronic
infections in mice. First, we tested the efficacy against acute
infection two weeks after the final/third immunization by
intraperitoneal inoculation (n = 15 mice/group) with 103
tachyzoites of a virulent T. gondii RH strain. The survival times
of all challenged mice were recorded daily. Secondly, we eval-
uated the level of protection induced by pVAX1-HSP40 against
chronic infection in mice (n = 15/group) challenged with 10
cysts of a mildly virulent cyst-forming Pru strain of T. gondii.
Mice were euthanized at 30 days post-challenge and their
brains were removed and individually homogenized in 1 mL
of PBS. The parasite cyst burden in the brain tissues of the
mice was determined by examining dilutions of DBL-stained
brain homogenates using a Zeiss wide-field epifluorescence
microscope with 10· objective, as previously described [12].
Determination of T lymphocytes in spleen tissue
Splenic single-cell suspensions prepared from all mice
prior to the challenge were used to analyze T lymphocytes
using flow cytometry, as previously described [22]. Briefly,
105 viable cells counted using a hemocytometer and 0.04% try-
pan blue dye (Bio-Rad) were suspended in 100 lL of 2% FBS
in PBS solution and incubated with 0.45 lL of FITC anti-
mouse CD3e, 0.25 lL of APC-eFluor780 anti-mouse CD4 or
0.25 lL of Percp-cy5.5 anti-mouse CD8a (eBioscience, San
Diego, California, USA) at 4 C for 30 min in the dark. After
two washes with 2 mL of PBS, the samples were re-suspended
in 300 lL of FACScan buffer (0.1% NaN3, 1% BSA) and
250 lL of 2% PFA solution for optical measurement. The data
from three independent experiments were obtained using the
FACScan flow cytometer and SYSTEM II software (BD
Bio-sciences, San Jose, California, USA).
Antibody detection using ELISA
Blood samples were collected from the ophthalmic
veins of three mice per group to assess the level of specific
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anti-anti-rHSP40 antibodies prior to each of the three immu-
nization doses and prior to the challenge using ELISA. Flat-
bottom 96-well plates were coated overnight at 4 C with
100 lL of rHSP40 protein containing approximately 1 lg of
the protein per well. Test sera diluted at 1:10 were added to
the wells and incubated for 1 h at 37 C. The antibody mea-
surement was carried out using SBA ClonotypingTM System/
HRP Kit (SouthernBiotech, Birmingham, Alabama, USA),
according to the manufacturer’s instructions (https://www.
southernbiotech.com/techbul/5300-05.pdf). The optical density
was measured using an ELISA reader (Bio-TekELx800,
Winooski, Vermont, USA) at 405 nm (OD405). Each sample
was tested in triplicate.
Lymphocyte proliferation assay
Splenic lymphocytes isolated from mice prior to chal-
lenge were cultured in 96-well plates at a concentration of
3 · 104 cells/well in 100 lL RPMI 1640 medium containing
10% fetal bovine serum in the presence of 10 lg/mL of ultra-
sonic extracts of whole T. gondii tachyzoites (TLA) for
72 h at 37 C in a 5% CO2 incubator. Lymphocytes incu-
bated in the absence of TLA extracts were used as non-
stimulated controls. Lymphocyte proliferation was assessed
using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS,
5 mg/mL, Promega) (MTS) assay. Absorbance was measured
at 490 nm. The results were expressed as stimulation indices
(SI), which were calculated as the ratio of OD490 values in
vaccinated and control groups. The data represent three inde-
pendent experiments.
Measurement of cytokines
To characterize the cytokine level profile in response to
immunization and prior to the challenge, we determined the
concentrations of IFN-c, IL-2, IL-4, IL-10, and IL-12p70 in
splenocyte culture supernatants using Legend MaxTM ELISA
Kits with Pre-coated Plates (Biolegend, San Diego, California,
USA). Splenocytes obtained from immunized mice and their
control counterparts at two weeks post final immunization were
cultivated in 96-well plates. The splenocyte culture supernatants
were collected at 24 h for the measurement of IL-2 and IL-4, at
72 h for themeasurement of IL-10, and at 96 h for the measure-
ment of IFN-c and IL-12p70. All samples were tested in
triplicate.
Statistical analysis
All data were analyzed using the SPSS13.0 Data
Editor (SPSS Inc., Chicago, Illinois, USA). Statistical differ-
ences among the four groups were determined by one-way
analysis of variance (ANOVA) with the Tukey post hoc test.
The differences in rates were analyzed by the student’s t-test.
Data are expressed as the mean ± standard deviation (SD).
The level of significance was defined as *p < 0.05 or
**p < 0.01.
Results
In vitro expression of pVAX1-HSP40
The results of immunofluorescence staining showed
immunofluorescence of HSP40 protein in the cytoplasm of
pVAX1-HSP40-transfected HEK293 cells (Fig. 1A), whereas
Figure 1. Immunofluorescence staining of HSP40 in HEK293 cells. HEK293 cells were transfected with pVAX1-HSP40 or pVAX1. At 72 h
after transfection, the cells were fixed, permeabilized, and incubated with anti-T. gondii primary antibody. The cells were then incubated with
fluorescein-conjugated secondary antibody and observed under a fluorescence microscope. The experiment was repeated three times,
yielding similar results. The cells transfected with pVAX1-HSP40 showed the immunofluorescence of HSP40 proteins in the cytoplasm (A),
whereas the cells transfected with the empty pVAX1 plasmid displayed little cellular immunofluorescence (B). Scale bar: 10 lm.
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cells transfected with pVAX1 displayed little cellular
immunofluorescence (Fig. 1B). Western blotting analysis
showed a single band (~46 kDa) of the expected molecular
size, indicating that pVAX1-HSP40 has been successfully
expressed in eukaryotic HEK293 cells (Fig. 2). There was no
protein band detected in the lysates of cells transfected with
the empty pVAX1 vector.
pVAX1-HSP40 protects mice against chronic
infection
After three booster immunizations using pVAX1-HSP40
with two-week intervals, Kunming mice were challenged
with 103 tachyzoites of T. gondii RH strain or 10 cysts of Pru
strain in order to evaluate the protective efficacies against
acute infection and chronic infection, respectively. The survival
of immunized and non-immunized mice following challenge
with T. gondii RH strain was monitored daily. As shown in
Figure 3, no significant difference in the survival between
pVAX1-HSP40-immunized mice (6.93 ± 1.28 d) and mice in
the non-immunized groups (6.53 ± 0.64 d for pVAX1,
6.40 ± 0.63 d for PBS, and 6.33 ± 0.62 d for healthy control)
was detected (p > 0.05). Interestingly, pVAX1-HSP40 immu-
nization achieved a significant reduction in the parasite cyst
burden in the brain of pVAX1-HSP40-immunized mice
(1871.9 ± 142.3) compared with that of mice in the control
groups immunized with pVAX1 (3479.2 ± 204.4), PBS
(3024.4 ± 212.8), and healthy control mice (3275.0 ± 179.8),
achieving 53.8%, 61.8%, and 57% reduction, respectively
(p < 0.01; Fig. 4).
Determination of T lymphocytes in spleen
tissues
The percentages of CD3e+CD4+ T and CD3e+CD8a+ T
lymphocytes in spleen of immunized mice prior to chal-
lenge were determined using flow cytometry. We observed
Figure 2. Western blotting of the expression of HSP40 protein
encoded by the plasmid pVAX1-HSP40 in vitro. One band of
approximately 46 kDa was detected in the pVAX1-HSP40-trans-
fected cells (Lane 1), whereas no band was detected in protein
extract of cells transfected with the pVAX1 control (Lane 2). M:
protein marker.
Figure 3. pVAX1-HSP40-based immunization failed to enhance
the survival of acutely infected mice. Immunized and non-
immunized mice were intraperitoneally challenged with 1 · 103
tachyzoites of T. gondii RH strain at two weeks post the final
immunization and their survival times were recorded daily until all
mice died. No statistically significant difference was observed
between control mouse groups (p > 0.05).
Figure 4. pVAX1-HSP40-based immunization protected against
chronic infection. Number of brain cysts in mice challenged orally
with 10 Pru cysts two weeks post the final immunization. The brain
cysts in the pVAX1-HSP40-immunized mice were significantly
lower compared with those in the control mouse groups
(**p < 0.01). No significant difference was detected between the
control mouse groups (p > 0.05).
Z.-Y. Li et al.: Parasite 2018, 25, 37 5
significant increases in the percentages of CD3e+CD4+ and
CD3e+CD8a+ T lymphocytes in pVAX1-HSP40-immunized
mice (22.0 ± 0.86 and 12.5 ± 0.78, respectively) compared
with mice vaccinated with pVAX1 (14.2 ± 1.53 and
6.5 ± 0.98); with PBS (13.7 ± 1.96 and 6.4 ± 1.02) and in
mice left non-immunized as healthy controls (15.2 ± 1.54 and
5.0 ± 0.33) (p < 0.05; Fig. 5).
Measurement of specific antibodies
in serum samples
As shown in Figure 6A, the levels of specific anti-
T. gondii rHSP40 antibodies in the mouse sera examined prior
to each of the three immunization doses, and prior to the
challenge, were not significantly different between pVAX1-
HSP40-immunized mice and mice from the three control
groups (pVAX1, PBS and healthy control) (p > 0.05). The
levels of IgG1 and IgG2a were determined two weeks after
the third immunization. One way ANOVA and Tukey’s multi-
ple comparisons test were used for statistical analysis of IgG1
and IgG2a data. The level of IgG2a was slightly increased in
the pVAX1-HSP40-immunized mice compared with mice in
all control groups, but the results was not statistically signifi-
cant (p > 0.05; Fig. 6B).
pVAX1-HSP40 immunization did not induce
lymphocyte proliferation
The in vitro lymphocyte proliferation assay revealed that
stimulation index of splenic lymphocytes from pVAX1-
HSP40-immunized mice was not significantly different
(p < 0.05) when compared with that of non-immunized
Figure 5. Flow Cytometry analysis of the proportion of T lymphocyte subclasses in mouse spleen. The CD3e+CD4+ T- and CD3e+CD8a+ T-
lymphocytes in spleen of pVAX1-HSP40-immunized mice were increased significantly compared with that of mice in the control groups
(p < 0.05). No significant difference was detected among the mice in the three control groups (p > 0.05).
Figure 6. Levels of specific anti-rHSP40 antibodies in the serum of pVAX1-HSP40-immunized mice. (A) The optical densities (OD405)
of total IgG prior to each of the three booster immunizations at 0, 2 and 4 weeks, and prior to the challenge at 6 week (i.e., two weeks
after the third immunization) using ELISA. (B) Levels of IgG isotypes, IgG1 and IgG2a, two weeks after third immunization (i.e., 6 weeks
after the primary immunization). There was no significant difference in the level of antibodies between immunized and control mice
(p > 0.05).
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controls, either in the presence of ConA or TLA (Fig. 7). This
finding suggests a lack of induction of lymphocyte prolifera-
tion responses to TLA after vaccination with pVAX1-HSP40.
Immunization did not influence the production of
cytokines
The concentrations of five cytokines (IFN-c, IL-2, IL-4,
IL-10, and IL-12p70) in splenic culture supernatants (Fig. 8)
were not significantly different between immunized and control
mice (p > 0.05).
Discussion
In the past few years, several attempts have been made to
develop a preventative strategy to control T. gondii infection,
such as using virulence-attenuated parasite strain and sub-unit
vaccines [2, 17, 18, 35, 39]. Currently, leveraging the eukary-
otic expression vector pVAX1 to develop DNA vaccine has
been the focus of intense research because it can activate both
innate and adaptive immune responses [41]. Interestingly,
HSP40 has been associated with the virulence of a number
of viruses and Apicomplexan protozoan parasites, and is con-
secutively expressed during the growth cycle of T. gondii, mak-
ing it a good vaccine candidate [4, 21, 30]. For these reasons,
the present study aimed to evaluate the protective efficacy of
pVAX1 encoding HSP40 against T. gondii infection in mice.
The recombinant DNA plasmid pVAX1-HSP40 was suc-
cessfully constructed and the expression of HSP40 in the trans-
fected HEK293 cells was confirmed using an indirect
immunofluorescent assay and Western blotting. This recombi-
nant plasmid was used to immunize SPF-grade female Kun-
ming mice for three sequential times with two-week
intervals. pVAX1-HSP40-immunized mice developed fewer
parasite cysts in their brain following oral challenge with 10
Pru cysts compared with non-immunized control mice. Specif-
ically, pVAX1-HSP40 achieved 53.8%, 61.8% and 57%
Figure 8. Levels of cytokines in splenocyte culture. Splenocytes
were obtained from immunized and control mice prior to the
challenge and cultivated in 96-well plates. The levels of IFN-c,
IL-2, IL-4, IL-10, and IL-12p70 cytokines in splenic culture
supernatants were determined using ELISA. No significant differ-
ence was detected between pVAX1-HSP40-immunized mice and
control mouse groups (p > 0.05).
Figure 7. Lymphocyte proliferation assay. Splenocytes were
obtained from immunized mice and the control groups prior to
the challenge and cultivated in 96-well plates. Lymphocyte stim-
ulation index was determined using the MTS assay. No significant
difference was detected between pVAX1-HSP40-immunized group
and control mice (p > 0.05).
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reduction in the parasite cyst burden, compared with cyst bur-
den using vaccination with pVAX1, PBS, and healthy control,
respectively. This result was higher than that obtained by DNA
vaccine expressing T. gondii CDPK3 [40] and 39.08% by DNA
plasmid (pVAX1-PF) encoding TgPF gene [13]. However, our
result was comparable to the 57.8% reduction achieved by vac-
cination using multiple antigenic peptides encapsulated by chi-
tosan microspheres [16].
In a striking contrast, the survival time of mice was not
significantly different between mouse groups challenged with
RH strain, indicating that sequential immunization with
pVAX1-HSP40 was effective at preventing the chronic, but
not acute infection with this parasite. Interestingly, the percent-
ages of CD3e+CD4+ T and CD3e+CD8a+ T lymphocytes in
the spleen of pVAX1-HSP40-immunized mice were signifi-
cantly increased in comparison with control groups, which is
consistent with previous studies [22, 38]. Both CD8+ and
CD4+ T cells play an important role in resistance to T. gondii
in mice [14, 26]; this was also indicated by the susceptibility of
individuals with T cell deficiencies to toxoplasmosis [25].
Thus, the significant activation of the subclasses of T lympho-
cytes in spleen of immunized mice may be a contributing
factor to the observed reduction in parasite cysts in the brain
of immunized mice challenged with T. gondii Pru strain.
Infection with T. gondii can trigger strong innate and
adaptive immune responses in the infected hosts [10, 28].
Th1-type cellular immune response during T. gondii infection
plays an important role in protecting hosts from acute infection
[11, 31]. Also, CD4+ cells and humoral antibody response
contribute to controlling T. gondii during chronic infection
by limiting development of the tissue cysts [19]. Therefore,
specific anti-T. gondii antibodies including total IgG and its
subclasses (IgG1 and IgG2a) were examined. Similar to other
T. gondii virulence factors, such as rhoptry protein 18 [38],
immunization with pVAX1-HSP40 was able to slightly
increase the production of specific antibodies (p > 0.05) and
only after the third booster immunization, indicating that the
strategy of using multiple sequential doses was necessary to
enhance the humoral immune response in the immunized mice.
A mixed Th1/Th2 immune response, slightly skewed towards
Th1-type response as indicated by a slightly higher lgG2a/
IgG1 ratio (p > 0.05), was detected in pVAX1-HSP40-immu-
nized mice (Fig. 6B). This result suggests that vaccination
using pVAX1-HSP40 can elicit a cell-mediated immune
response, which was anticipated from a DNA vaccine. How-
ever, this finding was not supported by the results of the lym-
phocyte proliferation assay or the concentrations of cytokines
(IFN-c, IL-2, IL-4, IL-10, and IL-12p70), which were not sig-
nificantly different between immunized and non-immunized
mice.
In conclusion, sequential immunizations with pVAX1-
HSP40 induced cellular immune responses and reduced the
number of brain cysts in mice challenged orally with Pru
strain. However, immunization had no influence on lympho-
cyte proliferation or the levels of cytokines. These data sug-
gest that T. gondii HSP40 may be a good DNA vaccine
candidate, which can be used together with other parasite pro-
teins to formulate a cocktail vaccine against chronic T. gondii
infection.
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